Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
AdAlta Ltd. ( (AU:1AD) ) has issued an update.
AdAlta Limited has accelerated its ‘East to West’ cellular immunotherapy strategy by signing two additional non-binding term sheets to in-license clinical stage CAR-T products, aiming to become a leader in cellular immunotherapy for solid cancer patients. This shift aligns with global trends of biopharma innovation from Asia transforming the industry, and AdAlta aims to enhance shareholder value by streamlining operations and focusing resources on this strategy, while advancing its antifibrotic molecule AD-214 through external partnerships.
More about AdAlta Ltd.
AdAlta Limited is a biotechnology company focusing on cellular immunotherapy, particularly in the development and in-licensing of innovative cell therapies for solid cancers. Their primary market focus is on leveraging Asian biopharma innovations to introduce them to Western regulated markets.
YTD Price Performance: -15.00%
Average Trading Volume: 344,238
Technical Sentiment Consensus Rating: Buy
Current Market Cap: A$10.73M
Learn more about 1AD stock on TipRanks’ Stock Analysis page.
